8-K
filed May 21, 2026, 4:13 PM ET
ticker ANIP
CIK 0001023024
other material
confidence high
sentiment neutral
materiality 0.50
ANI Pharma stockholders approve Amended 2022 Stock Plan, elect seven directors
ANI PHARMACEUTICALS INC
- Approved Amended 2022 Stock Plan; authorized share reserve increased by 962,000 to 8,222,000 shares.
- All seven director nominees elected: Haughey, Lalwani, Leonard, Pera, Shanmugam, Tannenbaum, Thoma.
- Ratified Ernst & Young as independent auditor for fiscal year 2026.
- Advisory say-on-pay vote approved; future votes to be held every one year.
- Amended plan includes no-hedging policy on repricing and director compensation cap of $750k per year.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANI PHARMACEUTICALS INC shareholders approved Approval of the compensation of the Company’s named executive officers, on an advisory basis.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
The vote with respect to the approval of the compensation of the Company’s named executive officers, on an advisory basis, was as follows: For Against Abstain Broker Non-Votes 13,819,988 1,058,460 17,377 2,030,222
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANI PHARMACEUTICALS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-12-31
Exact text from the filing
The vote with respect to the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: For Against Abstain 16,874,103 7,333 44,611
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANI PHARMACEUTICALS INC shareholders approved Approval of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers, on an advisory basis.
- Proposal
- say on pay frequency
- Outcome
- passed
Exact text from the filing
The vote with respect to the approval of the frequency of future advisory votes on the compensation of the Company’s named executive officers was as follows: ONE YEAR TWO YEARS THREE YEARS Abstain Broker Non-Votes 14,412,299 4,947 467,236 11,343 2,030,222
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANI PHARMACEUTICALS INC shareholders approved Election of seven director nominees.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The vote with respect to the election of each of the director nominees was as follows: Nominees For Against Abstain Broker Non-Votes Thomas Haughey 14,732,894 159,765 3,166 2,030,222 Nikhil Lalwani 14,873,796 15,198 6,831 2,030,222 Matthew J. Leonard, R.Ph. 14,743,471 149,095 3,259 2,030,222 Antonio R. Pera 14,542,012 350,649 3,164 2,030,222 Muthusamy Shanmugam 14,849,624 42,253 3,948 2,030,222 Renee P. Tannenbaum, Pharm.D. 14,063,620 829,566 2,639 2,030,222 Jeanne A. Thoma 14,565,758 327,393 2,674 2,030,222
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANI PHARMACEUTICALS INC shareholders approved Approval of the Amended 2022 Stock Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The vote with respect to the approval of the Amended 2022 Stock Plan was as follows: For Against Abstain Broker Non-Votes 13,806,050 1,080,387 9,388 2,030,222
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.